Completes $ 8.9 mil. private placement, which will be used primarily to fund expanded Phase II development of the biological response modifier Imuvert for the treatment of brain cancer. The Boulder, Colorado-based biotech firm said it "anticipates meeting with FDA in the very near future to discuss" whether Imuvert can be developed under FDA's new expedited approval procedures.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.